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The structure-function relationships of dystrophin, a protein which is absent or defective in patients with Duchenne or Becker muscular dystrophies, 
and utrophin can only be compared if specific antibodies are produced. We expressed C-terminal parts of dystrophin and utrophin in expression 
vectors. Mice were immunized with recombinant proteins and 26 monoclonal antibodies were produced and analyzed. Their respective pitopes 
were determined using other overlapping recombinant products. We observed antibody specificity towards 400 kDa dystrophin and/or utrophin 
protein bands, either by Western blot analysis or immunodetection i human skeletal (quadriceps) and smooth (uterus) muscles. These antibodies 
have been used to compare the relative abundance of both dystrophin and utrophin relative to the structures analyzed. 
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1. INTRODUCTION 
Duchenne muscular dystrophy (DMD) is a progres- 
sively degenerative lethal muscle disease promoted by 
the absence of dystrophin, a 400 kDa protein [l-3]. 
Becker muscular dystrophy (BMD) is a similar but 
milder disease due to the presence of an abnormal 
dystrophin. Dystrophin consists of four main domains 
characterized according to homology with other known 
cytoskeletal proteins [4-61. The molecule is enriched at 
the sarcolemmal membrane [7] where it is anchored by 
its C-terminal part [8,9]. It is thought to have a struc- 
tural and mechanical role [lO,l l] and to be involved in 
calcium ion channel regulation [ 12,131. 
However, studies on BMD patients have revealed a 
size-altered ystrophin molecule [14] and the presence 
of another molecule (400 kDa), named DRP (dystro- 
phin related protein). This new molecule, called utro- 
phin, was recently sequenced and presents homology 
with dystrophin mainly in its N- and C-terminal do- 
mains [15]. The gene is located on an autosomal chro- 
mosome, locus 6q24 [16], opposite the dystrophin gene, 
locus xp21 [17]. 
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In this study, two cDNA fragments derived from 
dystrophin or utrophin C-terminal sequences were ex- 
pressed as fusion proteins and monoclonal antibodies 
produced. Two other subfragments allowed us to map 
their epitopes. Western blot analysis and immunodetec- 
tion by optical microscopy methods were used to deter- 
mine their specificity towards dystrophin or utrophin. 
Our data on some specific dystrophin monoclonal anti- 
bodies also revealed a 77 kDa product, called DP71, 
derived from the Xp2 1 gene [181. 
2. MATERIALS AND METHODS 
2.1. Plasmid constructions 
Chicken skeletal dystrophin cDNA subclone 2 was obtained from 
Lemaire et al. [19]. The length of each produced fragment is indicated 
with a bar in Fig. 1. The different fragments were aligned according 
to their sequence homology, as shown by the relative positions of the 
bars. The characteristics of these fragments are given in Table I. 
The pEX1 vector gave rise to a construction which corresponded 
to a fusion protein with C-terminal 303 residues of chicken dystrophin 
(aa 3,357-3,660) at the end of B-galactosidase. This fusion protein 
expressed in E. coli is hereafter designated as fusion protein H. The 
H, fusion protein (127 amino acids) spanned residues 3,357 to 3,484 
and was produced by EcoRI/&mHI digestion of the starting cDNA 
dystrophin material. The H2 fusion protein (258 amino acids) spanned 
residues 3,357 to 3,615 and was obtained by NcoIlBamHI digestion. 
Both vectors were religated after Klenow fragment reatment. The H, 
fusion protein contained the last 90 residues of dystrophin and was 
produced by cloning the PvuIIIHindIII fragment of H in the pMAL 
vector. 
The last expressed fusion protein inserted into the EarnHI site of 
vector pEX3 was obtained according to the procedure described by 
Khurana [20] and contained 227 residues from the C-terminal end of 
utrophin, i.e. amino acids 3,161* to 3,388* (*: relative to the human 
utrophin sequence). This fragment is hereafter designated as K. 
Published by Elsevier Science Publishers B. V. 
Volume 322, number 1 FEBS LETTERS May 1993 
2.2. Purijication of recombinant proteins 3. RESULTS AND DISCUSSION 
The pEX recombinant proteins were purified as described previ- 
ously [21]. 
The pMAL recombinant protein was produced as specified by the 
manufacturer (09). Briefly, induction of the recombinant protein 
with 0.3 mM IPTG was performed for 2 h when OD (600 nm) reached 
0.6. Sonication of bacterial pellets resuspended in lysis buffer (phos- 
phate buffer 10 mM, NaCl30 mM, Tween 20 0.25%,/7-mercaptoetha- 
no1 10 mM, EDTA 10 mM, EGTA 10 mM, pH 7) and centrifugation 
at 8,000 x g for 25 min after the addition of NaC10.5 M (final concen- 
tration) allowed us to obtain a soluble fraction which was loaded after 
4-fold dilution on an amylose resin column. The protein was eluted 
with maltose 10 mM contained in the column phosphate buffer (10 
mM, NaC10.5 M, /3-mercaptoethanol 10 mM, EGTA 1 mM, pH 7). 
3.1. Expression of fusion proteins 
2.3. Antibody production 
Two sets of antibodies were produced from selective fusion proteins 
expressing either C-terminal dystrophin (H protein with residues 3,357 
to 3,660) or C-terminal utrophin (K protein with residues 3,161* to 
3,388*) sequences in E. coli. 
The different produced fusion proteins correspond- 
ing to different parts of dystrophin or utrophin are 
shown in Fig. 1. They were characterized by poly- 
acrylamide gel electrophoresis. The expected sizes of 
each recombinant protein (Table I) were always com- 
patible with the calculated molecular weight (MJ. For 
pEX constructions, the 108 kDa part corresponding to 
/&galactosidase was fused to the cloned sequences. For 
pMAL construction, the 42 kDa part corresponding to 
the maltose binding protein was fused to the dystrophin 
sequence. 
3.2. Characterization of the raised antibodies 
2.4. SDS-PAGE and immunoblots 
Human skeletal tissue and purified fusion proteins were homoge- 
nized in 100 mM Tris HCl, pH 8.0, 5% SDS containing 10 mg/ml 
PMSF, 1 mg/ml leupeptin, 10 mg/ml soybean trypsin inhibitor, 1 
mg/ml iodoacetamide and boiled for 5 min in the presence of an equal 
amount of loading buffer. Samples were applied on 0.75 mm SDS- 
polyacrylamide gradient gel containing 25% glycerol with no stacking 
gel. Western blot conditions were carried out as previously described 
[22,23]. 
2.5. Immunoaktection by optical microscopy 
Transverse cryostat sections of human skeletal (quadriceps) and 
smooth (uterus) muscles were treated with specific dystrophin or utro- 
phin antibodies and then revealed with peroxidase-linked antibodies. 
H and K fusion proteins provided us with 10 and 16 
different monoclonal antibodies, respectively. Each 
were analyzed by ELISA titration curves and Western 
blots against both H or K antigens. Only 3 antibodies 
(designated H 4B9, H 12G9 and H 2A12) were specific 
to the Xp21 dystrophin locus since they detected only 
the H protein and did not react with the K protein. 
Their location was further restricted to H, as they de- 
tected both H, and Hz proteins but not H3 protein. Due 
to the sequence homology between dystrophin and 
utrophin, two potential sites for these antibodies were 
thought to correspond to residues 3,4143,421 and 
3357 3484 
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Fig. 1. Linear diagram of dystrophin and utrophin C-terminal domain constructions. Hl (lane a), H2 (lane b), H3 (lane c), H (lane d) and K (lane 
e) constructions were aligned according to their sequences. Localization of the specific monoclonal antibodies ites are indicated by solid boxes. 
Black boxes labelled with number 1 means that the antibodies were specific to the Xp21 locus. Dark-dashed boxes labelled with number 3 means 
that the antibodies were specific to the 6q24 locus. Clear-dashed boxes labelled with number 2 means that the antibodies were specific to either 
locus Xp21 or 6q24. For the H, H,, H2 and H, fragments, the sequence numbering was given according to the chicken dystrophin sequence. For 
the K fragment, the sequence numbering was given according to the human utrophin sequence and noted with an asterisk. 
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Table I 
Characteristics of the different dystrophin and utrophin recombinant protein C-terminal parts obtained 
May 1993 
Expression vector Fusion protein Insert cDNA (bp) Amino acid sequence Mw (kDa) Protein size 
pEX1 H 1,050 3,357 -3,660 33.3 141.3 
pEX1 H, 381 3,357 -3,484 14 122 
pEX1 HZ 774 3,357 -3,615 28.4 136.4 
pMAL H, 408 3,570 -3,660 9.9 51.9 
pEX3 K 681 3,161*-3,388* 24.9 132.9 
The cDNA fragments used for H and H, cloning include a small part which is not translated. This explains the difference observed in length with 
the deduced amino acid sequence. * corresponds to the numbering of the recently reported human utrophin sequence [15]. 
3,459-3,466. They belonged to the group that we called 
la (Table II and Fig. 1, lane d). A commercially availa- 
ble antibody (DyB; no. 4 on Table II) was also found 
to be specific to the Xp21 dystrophin molecule since it 
detected only H and H, fragments. It was classified as 
belonging to group lb (Fig. 1, lane d), since it was 
directed against the dystrophin C-terminal 17 residues 
[24], a region which did not provide us with any anti- 
bodies. 
Among the 16 antibodies which were produced from 
IS protein, 9 were specific to the 6q24 utrophin locus 
since they only detected K protein. They belonged to 
group 3 (Table II). According to the sequence homol- 
Table II 
ELISA titration of the different antibodies obtained and their classifi- 
cation into 3 Groups 
Antibodies ELISA H ELISA K Group 
1 H12G9 
2 H2A12 
3 H4B9 
4 Dys2 
5 H’2Hll 
6 H’lOA3 
7 H’3E7 
8 H’4Al 
9 H’4ClO 
10 H’5A3 
11 K’14H9 
12 K’4A8 
13 K’4D9 
14 K’5Bl 
15 K’5B4 
16 K’7G12 
17 K’8Ell 
18 K’8G9 
19 K14A7 
20 K14G6 
21 K2A4 
22 K2B12 
23 K4C6 
24 K7H9 
25 K8C6 
26 K9D6 
27 K9E12 
l/l ,300 
l/1,000 
11800 
l/1,500 
1/10,000 
l/200 
l/240 
l/420 
l/150 
l/1,100 
l/100 
l/600 
11220 
l/100 
l/480 
117 
112 
l/7 
_ la 
_ la 
_ la 
_ lb 
112,900 2 
11700 2 
l/1,100 2 
l/4,200 2 
11100 2 
113,000 2 
113,750 2 
l/1,200 2 
l/800 2 
l/2,250 2 
111,000 2 
1114 2 
l/400 2 
l/14 2 
112 3 
l/260 3 
112 3 
11200 3 
l/1,800 3 
1160 3 
112 3 
l/325 3 
l/850 3 
Group la and lb antibodies pecifically recognized ystrophin, Group 
2 antibodies recognized both proteins and Group 3 specifically recog- 
nized utrophin. 
ogy between dystrophin and utrophin, five potential 
sites for these antibodies could correspond to residues 
3,161*-3,175*, 3,210*-3,217*, 3,295*-3,305*, 3,3 1*- 
3,356* and 3,372*-3,387* (Fig. 1, lane e). 
Other antibodies were designated as K’ or H’ accord- 
ing to their parental origin and belonged to group 2 (see 
Table II). They detected both H and K proteins but did 
not detect H, or H3 proteins. This allowed us to map 
their epitopes on residues 3,4853,518 and 3,530-3,570 
on the H fragment and on residues 3,261*-3,294* and 
3,307*-3,345* on K fragment (Fig. 1, lanes d and e). We 
noticed that all group 2 antibodies always showed better 
titrations with K than with H fusion proteins. 
One antibody of each group was used for immunol- 
ogical detection of dystrophin and utrophin by Western 
blot analysis and histochemical detection in human tis- 
sues to check the efficiency of the above monoclonal 
antibodies relative to their specificity. 
3.3. Western blot analysis 
Crude skeletal muscle extracts from a BMD patient 
were used for Western blotting. This previously ana- 
lyzed patient [25] had a 300 kDa reduced-size dystro- 
phin and also a 400 kDa protein band corresponding to 
utrophin. This was clearly demonstrated with each 
monoclonal antibody of each group, as shown in Fig. 
2. Group 2 (H’5A3) showed a faint 400 kDa utrophin 
band and a strong 300 kDa dystrophin band. Group la 
(H12G9) showed only the 300 kDa reduced-size dystro- 
phin band and Group 3 (K4C6) showed only the 400 
kDa utrophin faint band. 
Crude brain and skeletal muscle extracts from rat 
were also obtained and used for Western blotting. Anal- 
kDa I A B C ~~- -_ 
400 - 
300 - 
Fig. 2. Western blots for dystrophin and utrophin detection. Compar- 
ison of Group 1 (B), Group 2 (A) and Group 3 (C) antibodies on 
previously used BMD crude skeletal muscle extract [18,22]. 
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ysis with H’ or H antibodies revealed, in the brain but 
not in the skeletal muscle, the 400 kDa dystrophin band 
and also a 77 kDa protein band (Fig. 3). This band 
corresponded to the small transcript product of the 
dystrophin gene which has already been described [26] 
and called DP71. 
3.4. Immunohistological analysis 
Dystrophin specific antibodies stained the human 
skeletal muscle cell (Fig. 4B) and the smooth muscle cell 
peripheries (Fig. 5B). Detection was performed using 
two specific antibodies (left panel H12G9, right panel 
H4B9) and gave similar patterns. Utrophin specific an- 
tibodies also stained the human skeletal muscle cell 
(Fig. 4C) and the smooth muscle cell peripheries (Fig. 
5C). Each specific utrophin antibody (left panel K4C6, 
right panel K9E12) gave faint detection in comparison 
to dystrophin antibodies in the skeletal muscle cells and 
all cells, regardless of their size, were underlined by 
utrophin antibodies. Both dystrophin and utrophin an- 
tibodies stained with a rather similar pattern the smooth 
muscle fibres, opposite the skeletal muscle fibres. A very 
strong staining was observed with the vessel wall which 
was even more intense in the human smooth muscle 
(Fig. 5C) than in the human skeletal muscle (Fig. 4C). 
These differences might not result from the different 
accessibility of the epitope sites since two antibodies of 
each group gave the same result but could reflect the 
natural abundance of the antigens present in these tis- 
sues. The NMJ were also stained with these antibodies 
(not shown) and allowed us to confirm that both dystro- 
phin and utrophin were present in this particular struc- 
ture in agreement with recent reports [25,27]. 
B 
12 12 
Fig. 3. Western blots for dystrophin and DP71 detection. Comparative 
detection of the 400 kDa dystrophin band and the 77 kDa band, called 
DP7 1, on rat brain (1) or skeletal muscle (2) crude extracts. (A) Group 
2 antibody (H’SA3), (B) Group 1 antibody (H12G9). 
C 
Fig. 4. Immunofluorescence detection of dystrophin and utrophin in 
human skeletal muscle (quadriceps). (A) PBS control, (B) Xp21 spe- 
cific monoclonal antibody: left panel H12G9, right panel H4B9, (C) 
6q24 specific monoclonal antibody: left panel K4C6, right panel 
K9E12. Bar corresponds to 20 pm. 
The generation of new specific monoclonal antibod- 
ies directed against dystrophin or utrophin will be essen- 
tial to prevent misinterpretations concerning localiza- 
tion of these proteins and to carry out more precise 
13 
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Fig. 5. Immunofluorescence d tection of dystrophin and utrophin in 
human smooth muscle (uterus). (A) PBS control, (B) Xp21 specific 
monoclonal antibody: left panel H12G9, right panel H4B9, (C) 6q24 
specific monoclonal antibody: left panel K4C6, right panel K9E12. 
Bar corresponds to 20 pm. 
diagnostic studies on muscles of BMD/DMD patients 
and patients with related muscular disorders. But the 
fact that specific dystrophin monoclonal antibodies also 
reacted with DP 71, especially in non-muscle tissues 
14 
such as brain, might make immmunofluorescence anal- 
ysis difficult to interpret because of the lack of informa- 
tion concerning DP71 distribution within cells. 
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